Core Viewpoint - Sichuan Mairidi Medical Technology Co., Ltd. has completed several million yuan in angel round financing, primarily aimed at developing high-load nuclear medicine projects and building a radioactive drug pilot platform [1] Group 1: Financing Details - The financing round was led by the Provincial Science and Technology Innovation Investment Academy, Western Achievement Transformation Center, Xianyang Financial Investment, Guosheng Innovation, and Mairike [1] - The funds will be used for the development of precise and controllable high-load nuclear medicine projects and the construction of a radioactive drug pilot platform, leveraging microfluidic technology [1] Group 2: Company Overview - Mairidi was established on December 12, 2024, with a registered capital of 1.1337 million yuan, focusing on innovation in the fields of oncology and neurology [1] - The company was jointly initiated by the microfluidic technology team from Sichuan University and experts from the Nuclear Medicine Department of West China Hospital, aiming to overcome existing technological bottlenecks and pioneer the application of microfluidic technology in nuclear medicine [1] Group 3: Ownership Structure - The actual controller of Mairidi is Zhang Chuan, who holds a total shareholding ratio of 43.86% and has 88.21% of the voting rights [1] - Zhang Chuan currently serves as the chairman and manager of the company [1]
迈锐迪完成数千万元天使轮融资，董事长张川控股88%表决权